P3 Health Partners

Rising Medicare Eligibility And Value-Based Care Will Expand Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

09 Apr 25

Updated

07 Dec 25

Views

17

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-51.4%

7D

-9.1%

Loading

1Y

-51.4%

7D

-9.1%

You can edit this narrative until Dec 8 9:10 AM. Then, changes will post as Updates.

Author's Valuation

US$10.2555.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 07 Dec 25

PIII: Operational Progress And 2026 Earnings Ramp Will Drive Long-Term Upside

Narrative Update on P3 Health Partners The analyst price target for P3 Health Partners has been reduced from $20.00 to $12.50 per share, as analysts cite disappointing recent aEBITDA and growing confidence that operational progress will support a stronger 2026 earnings profile. Analyst Commentary Recent commentary reflects a mixed but generally constructive view on P3 Health Partners, with the lowered price target framed as a recalibration of expectations rather than a loss of confidence in the long term earnings trajectory.

Shared on 23 Nov 25

Fair value Decreased 27%

PIII: Margin Expansion And Industry Tailwinds Will Drive Long-Term Upside

Analysts have revised their price target for P3 Health Partners downward from $14.00 to $10.25 per share, citing disappointing recent results. However, they maintain optimism for long-term improvement based on projected growth and margin trends.

Shared on 29 Aug 25

Fair value Increased 75%

The notable upward revision in P3 Health Partners’ price target is primarily supported by a significant decline in its forward P/E ratio, indicating improved earnings expectations, with the fair value estimate increased from $8.00 to $14.00. What's in the News P3 Health Partners raised earnings guidance, projecting total revenues between $1.35 billion and $1.5 billion for fiscal 2025.

Shared on 01 May 25

Fair value Decreased 75%

Shared on 24 Apr 25

Fair value Decreased 48%

AnalystConsensusTarget has decreased future PE multiple from 4.4x to 2.2x.

Shared on 17 Apr 25

Fair value Increased 673%

AnalystConsensusTarget has decreased revenue growth from 2.5% to 1.6%, increased future PE multiple from 1.0x to 4.4x, decreased discount rate from 10.2% to 9.0% and increased shares outstanding growth rate from 0.0% to 0.1%.

AnalystConsensusTarget Fair Value

US$10.25

55.3% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

11.60%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.50%

Calculation

US$105.40m

Earnings '28

x

0.46x

PE Ratio '28

=

US$49.00m

Market Cap '28

US$49.00m

Market Cap '28

/

3.36m

No. shares '28

=

US$14.60

Share Price '28

US$14.60 Share Price '28

Discounted to 2025 @ 12.50% p.a.

=

US$10.25

Fair Value '25